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ABSTRACT
Introduction: The objectives of the study are twofold.
First, to calculate healthcare resource utilisation and
costs for a cohort of adult overweight and obese
patients observed in primary and hospital care centres
during eight consecutive years (2003e2010) in an
urban setting in Spain. An analysis of whether these
costs vary by groups of individuals and types of
disease, and of how they compare with the previous
literature, is carried out in order to predict actions or
policies for resource optimisation. The second
objective is to estimate the impact of overweight and
obesity on the consumption of resources and costs,
accounting for a wide array of controls.
Methods and analysis: Observational and
retrospective cohort data are used, consisting of
medical records of patients followed up in outpatient
and hospital care facilities during the years
2003e2010. Three cohorts of patients are analysed:
normal weight (18.5$ body mass index (BMI) <25),
overweight (25$ BMI <30) and obese (BMI $30);
BMI is computed using clinical information. Individual-
level data on comorbidity, resource utilisation and
costs are available, and external information provided
by the population census regarding socioeconomic
status is used. Utilisation and associated costs across
BMI groups are compared by computing ratios for
overweight and obese individuals relative to those of
normal weight. Count data regression models (hurdle
and ﬁnite mixture models) are used, together with two-
part model regression models and taking into account
the panel structure of the data set to explore the
impact of overweight and obesity on the increased
utilisation of health services and costs, accounting for
a wide set of controls.
BACKGROUND
Obesity is the accumulation of excessive fat in
the body. Its prevalence has tripled in Europe
over the last two decades, and it is estimated
that 150 million adults and 15 million chil-
dren and adolescents in the region are
obese.
1 A similar trend is observed in the
USA, and Spain is likewise no exception, with
an estimated 37.8% (15.6%) of Spanish
adults being overweight (obese).
2 For
the EU15, annual deaths attributable to
overweight were 7.7%, ranging from 5.8% in
France to 8.7% in the UK. One of every 13
deaths per year produced in the European
Union is probably related to excess weight.
34
Although obesity is considered a multifac-
torial chronic disease linked to genetic,
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Open Access Protocolperinatal, socioeconomic and other factors, it is
primarily the consequence of an energy imbalance.
5e8
The epidemic is a major public health concern as it is
a key risk factor for a range of chronic conditions (ie,
hypertension, diabetes, dyslipidaemia, heart disease,
stroke, narcolepsy, osteoarthritis, asthma, apnoea, gout
and certain cancers), which tend to reduce quality of life
and ultimately cause death.
91 0In addition, most of these
patients suffer from mental disorders and perceived
social rejection leading to loss of self-esteem, a particu-
larly sensitive concern in children.
11
As a consequence of its high prevalence and association
with multiple chronic illnesses, obesity tends to substan-
tially increase healthcare resource utilisation and costs.
Two different approaches may be identiﬁed in the liter-
ature for analysing the relationship between obesity and
healthcare costs. First, there are those studies that present
estimates of the direct costs of obesity at the national
level. For instance, it is estimated that the proportion of
national healthcare expenditure attributable to obesity
ranges from 5.3% to 7.0% for the USA
12e17 and from
0.7% to 2.6% for other countries.
18 However, some
authors report that the cost of obesity could reach 7% of
total healthcare expenditure in Spain.
19 Within this
strand of literature, another set of papers estimates
medical costs and obesity based on survey data.
20e25
The second approach takes a lifetime perspective
based on retrospective databases or medical record
reviews and aims to estimate the impact of body mass
index (BMI) categories on use of resources and direct
costs for a set of related diseases. Most of these studies
are drawn from US data,
26e35 with very few referring to
other national contexts.
36e38 When production losses,
reduced labour productivity, higher rates of work
disability and lower salaries (due to problems of absen-
teeism, fewer job promotions or patterns of social
exclusion) are added to healthcare costs, the obesity
epidemic accounts for a larger fraction of GDP.
39 40
OBJECTIVES
The objectives of the study are twofold. First, to assess
the magnitude of the incremental use of healthcare
resources and their associated costs for a population of
adult overweight and obese patients compared with
normal weight individuals observed in primary care and
hospital facilities over a period of eight consecutive years
(2003e2010). An analysis of whether these additional
costs vary by groups of individuals and types of disease,
and of how they compare with previous related studies, is
carried out in order to predict actions or policies for
resource optimisation. The second objective is to
explore the impact of overweight and obesity on the
consumption of resources and costs, accounting for
a wide array of controls.
METHODS/DESIGN
Study design and population
We use observational, longitudinal and retrospective
data based on medical records of patients followed up in
primary care and hospital facilities. The study popula-
tion comprises patients from six primary care centres
(Apenins-Montigala `, Morera-Pomar, Montgat-Tiana,
Nova Lloreda, Progre ´s-Raval and Marti i Julia `) and two
reference hospitals (Hospital Municipal de Badalona
and Hospital Universitari Germans Trias i Pujol), serving
>110000 inhabitants in the north-eastern area of
Barcelona. This population is mostly urban, of lower-
middle socioeconomic status and from a predominantly
industrial context.
The study includes all patients aged 18 years and over
who were seen from 1 January 2003 to 31 December
2010 and who were regularly assigned to the above-
mentioned healthcare centres during the study period.
We exclude subjects who were transferred or moved to
other centres, patients from other areas or regions. The
resulting study population included approximately
112000 individuals (50.48% women; mean age
42.7 years).
Data
Overweight and obesity are assessed for each patient
through the BMI (kilograms per square metre),
computed from measured weight and height, and three
cohorts are distinguished: normal weight (18.5$ BMI
<25), overweight (25$ BMI <30) and obese (BMI $30).
Given that not all patients were measured annually,
we will need to assume BMI stability over the
analysed period. That is, BMI will be imputed for those
individuals with a small number of measurements and
interpolated when having partial information. Mirroring
previous literature, the measures for the utilisation of
healthcare resources analysed in this study are medical
visits (primary care, specialist care and emergency visits),
the number and duration of hospital visits, laboratory
and radiology tests, diagnostic or therapeutic tests,
referrals and drug prescriptions deﬁned annually. We
hypothesize that the consumption of resources and
medical costs incurred by overweight and obese patients
differ from those of normal weight patients.
As for chronic conditions, the number of health
problems per patient/year (mean episodes/patient) is
considered as a process of care comparable to a disease
diagnosis. According to the International Classiﬁcation
of Primary Care (ICPC-2), we account for a wide set of
conditions related to overweight and obesity: hyperten-
sion (K86, K87), diabetes mellitus (T89, T90), dyslipi-
daemia (T93), smoking (P17), alcoholism (P15, P16), all
types of organic failures (heart, liver and kidney),
stroke/cerebrovascular accident (K90), cerebrovascular
disease (K91), pulmonary embolism (K93), chronic
obstructive pulmonary disease (R95, chronic airﬂow
obstruction), bronchial asthma (R96), dementia or
memory disorders (P70, P20), neurological diseases
(Parkinson’s disease (N87), epilepsy (N88), multiple
sclerosis (N86) and other neurological diseases (N99)),
depression (P76) and malignant neoplasms (all types,
A79, B72e75, D74e78, F75, H75, K72, L71, L97,
N74e76, R84e86, T71e73, U75e79, W72e73, X75e81,
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diseases associated with each patient.
To compute comorbidity for each treated patient, we
use two indices: (1) the Charlson comorbidity index
41 as
a proxy for patient acuity and (2) the individual case-mix
index obtained from the ‘Adjusted Clinical Groups’
(ACG), a patient classiﬁcation system for iso-consumption
of resources.
42 A task force consisting of ﬁve professionals
(a document administrator, two clinicians and two tech-
nical consultants) will be set up to convert (map) the
ICPC-2 episodes to the International Classiﬁcation of
Diseases (ICD-9-CM). The criteria used will vary
depending on whether the relationship between the
codes is null (one to none), univocal (one to one) or
multiple (one to many). The operational algorithm of the
Grouper ACG Case-Mix System consists of a series of
consecutive steps to obtain the 106 mutually exclusive
ACG groups, one for each patient. The application of
ACG provides the resource utilisation bands so that each
patient, depending on his/her overall morbidity, is
grouped into one of ﬁve mutually exclusive categories
(1: healthy users or very low morbidity; 2: low morbidity;
3: moderate morbidity; 4: high morbidity and 5: very high
morbidity).
The data set includes other relevant information for
the empirical analysis, such as the patient’s age, gender,
employment status (active/retired), place of birth and
habitual residence, date of admission and discharge,
type of healthcare professionals contacted and reason
for the visit. Likewise, we include other confounding
factors such as smoking and drinking status among
others. In addition, data retrieved from the population
census will allow us to consider other socioeconomic
information, such as the distance from the current place
of residence to the healthcare centre, educational level
and marital status. Finally, an ID variable will capture
information regarding other household individuals
related to the patient.
Model of use of resources and costs
The design of the costs system is deﬁned by taking into
account the characteristics of the organisation, reporting
requirements and the degree of development of the
available information systems. The cost per treated
patient during the study period is taken as the unit of
measurement. The adaptation (conciliation or depu-
ration) of incurred expenditures from the Proﬁt and
Loss Statement (Financial Accounting) to the costs of
Analytical Accounting is carried out in two stages: (1) the
conversion of natural expenditures into costs and (2)
the allocation and classiﬁcation of costs. Those expen-
ditures not directly related to care (eg, ﬁnancial
spending, losses due to ﬁxed assets, etc) are excluded
from the analysis. Depending on volume of activity, we
consider two types of costs: ﬁxed or semi-ﬁxed costs and
variable costs. The former include personnel (wages and
salaries, indemniﬁcations and social security contribu-
tions paid by the company), consumption of goods
(medicines, intermediate products, health material and
instruments), expenditures related to external services
(cleaning and laundry), structure (building repair and
conservation, clothes and ofﬁce material) and manage-
ment of healthcare centres, according to the Spanish
General Accounting Plan for Healthcare Centres. Vari-
able costs are those related to diagnostic and therapeutic
tests and referrals.
More speciﬁcally, the concepts analysed are (1)
complementary tests, including (a) laboratory tests
(haematology, biochemistry, serology and microbiology:
average cost per request), (b) conventional radiology
(plain ﬁlms requests, contrast radiology, ultrasound
scans, mammograms and radiographs: expenditure per
request) and (c) complementary tests (endoscopy, elec-
tromyography, spirometry, CT, densitometry, perimetry,
stress testing, echocardiography, etc: expenditure per
request); (2) pharmaceutical prescriptions (acute,
chronic or on demand: retail price per package at the
time of prescription) and (3) referrals made to refer-
enced specialists or to hospital centres on either an
ordinary or emergency basis. From semi-ﬁxed costs, we
derive an estimation of the average cost per medical visit.
Table 1 shows an estimate of the resulting rates for the
years 2003 and 2009.
The different unitary cost rates used in the calcula-
tions are derived from cost accounting carried out by
primary healthcare and hospital centres for the available
years, from invoices of intermediate products issued by
different providers and from prices set by CatSalut
(Catalan Health Service). Therefore, total medical cost
per patient in each period will be calculated as semi-
ﬁxed costs (average cost per visit multiplied by the
number of medical visits) plus variable costs. In this
study, we do not account for the computation of ‘out-
of-pocket payments’ paid by the patient or family that
are not registered in the database. Healthcare costs will
be adjusted for each period according to the Consumer
Price Index.
Table 1 Estimates of unitary costs per patient in 2003 and
2009
Healthcare resources
Unitary
costs (V)
Unitary
costs (V)
Year 2003 Year 2009
Medical visits
Visit to medical primary care 15.02 22.74
Visit to emergency care 73.80* 115.23
Hospitalisation (per day) 201.50* 314.61
Visit to specialist care 66.20* 102.36
Complementary tests
Laboratory tests 17.69 21.86
Conventional radiology 14.02 18.14
Diagnostic/therapeutic tests 19.21 36.45
Pharmaceutical prescriptions PVP PVP
Source: Own analytical accounts.
*These ﬁgures were estimated using the growth rate experienced
by primary care visits during the period 2003e2009. PVP is retail
price.
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We begin the statistical analysis by carefully reviewing
our data set through a series of exploratory analyses in
order to detect possible mistakes in coding. Descriptive
and univariate statistical analyses are also performed
regarding the main variables of interest, while the pres-
ence of outliers is detected by means of ad-hoc tech-
niques (Hadi method) or graphical representation using
box plots. Stochastic kernels are estimated in order to
observe the characteristics of the distributions.
Given the above-mentioned objectives, the statistical
approach of the study is then divided in two stages. In
the ﬁrst stage, we calculate use and cost (total and by
sub-categories) of the considered healthcare services,
differentiating by BMI groups for the period 2003e2010.
Annualised means are computed for each measure of
interest. In order to compare resource utilisation and
associated costs across BMI groups, we will compute
ratios for overweight and obese individuals relative to
those with normal weight.
In the second stage, we use standard count data
regression models (ie, hurdle and ﬁnite mixture models),
together with a two-part regression models, taking into
account the panel structure of the data set, to explore the
impact of overweight and obesity on the utilisation of
health services and costs, accounting for a wide set of
controls. Sensitivity analysis is also performed based on
thresholds that deﬁne overweight and obesity, levels
of use of healthcare resources outside the extreme
percentiles and the problems caused by ‘attrition’.
43 44
Study timeline
Phases 1e2. Meeting to decide general planning of the
study. Tasks will be assigned to investigators and infor-
mative meetings held with physicians from participating
primary healthcare centres. Posterior follow-ups will be
quarterly. A bibliographic and document search will be
carried out and a structured summary drawn up. Time:
1 month.
Phase 3. Preparation of the database and collection of
patient variables (quantitative information).
This includes (1) design and drawing up of
a morbidity database (care episodes attended by
patient/year), (2) design and drawing up of a pharma-
ceutical prescription database, (3) design and drawing
up of a database covering healthcare services use and
direct costs (laboratory, radiology, referrals and phar-
maceutical prescription per patient/year) and (4)
obtaining an ACG per patient/year. Time: 2 months.
Phase 4. Validation of data quality. Veriﬁcation of
univariate results by ranges. Identiﬁcation of inadequate
categories. Time: 1 month.
Phase 5. Data analysis, including: (1) statistical anal-
ysis: descriptive, bivariate and multivariate analysis and
regression analyses and (2) interpretation of the results.
Time: 2 months.
Phase 6. Scientiﬁc diffusion of the results: this will
include the writing and publication of the results
obtained. Time: 1 year.
DISCUSSION
No previous study on the calculation of healthcare use
and costs according to BMI categories have been
computed in Spain taking into account a longitudinal
perspective. This protocol study aims to cover this gap.
Among the strengths of the study, we can remark that
we use population data, low cost based in electronic
medical records and long follow-up information. Possible
limitations of the study relate to the categorisation of
diseases, the possible bias in patient classiﬁcation, the
selection of therapeutic groups, the extent of operating
costs attributable to the information system, the potential
impact of disease under-reporting, the variability of
professional practice and information biases related with
retrospective observational data. Further research is
needed regarding cost-effectiveness and the delay in
diagnosis and treatment, as well as to replicate the study
in other healthcare organisations. Despite the success of
care for patients with chronic diseases such as obesity,
interventions should be based on multidisciplinary teams
so as to promote effective interventions in which patients
are highly engaged in self-care.
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